Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million
J&J Vision’s Q1-2024 global surgical revenue totaled $348 million, up 0.3 percent (+1.1 percent cc) over $347 million in Q1-2023, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Ap...
BVI Medical Launches Podeye Hydrophobic Monofocal IOL in Japan
BVI Medical announced April 17 that it had launched its Podeye hydrophobic monofocal IOL in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency. The lens was set to...
SalioGen Selects Gene Therapy Candidate to Develop for Stargardt
SalioGen Therapeutics announced April 17 that it had chosen a development candidate, SGT-1001, for the treatment of Stargardt disease. SGT-1001 is being developed as a one-time, non-viral gene ther...
US FDA Backs Call to Eliminate Interchangeability Designation for Biosimilars
A US FDA official has expressed support for measures before Congress to remove the interchangeability designation for biosimilars, claiming that the two-tier system is only causing confusion. Under...
Japanese IOL Maker Hoya Halts Production After Cyberattack
Japanese intraocular lens maker Hoya reported on April 4 that production of several of its products had stopped after a computer system failure, “most likely caused by unauthorized access” to its s...
Pravin Dugel, MD, Becomes President, CEO of Ocular Therapeutix
Ocular Therapeutix announced April 15 that its executive chairman, Pravin Dugel, MD, would assume the roles of president and chief executive officer, and that Antony Mattessich is stepping down, ef...
Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme
Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...
US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea
The US Justice Department has accused New York-based Regeneron of fraudulently manipulating Medicare’s drug pricing process for Eylea, costing the Medicare system hundreds of millions of dollars. T...
US Private Equity Firm Warburg Pincus Buys Controlling Stake in India’s Appasamy
US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid
Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis
Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate
Ocugen announced April 8 that the US FDA had cleared the company’s investigational new drug (IND) amendment to initiate a Phase III clinical trial of OCU400, a modifier gene therapy candidate for r...
Past News Stories
Rayner Marks Sale of 5 Millionth RayOne IOL
UK-based Rayner reported April 3 that it had sold its 5 millionth RayOne lens and 11 millionth lens made from RayAcryl, Rayner’s proprietary hydrophilic acrylic material. Rayner, founded in 1910, r...
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative-free, single-use, once-daily ey...
Viatris, Ocuphire Announce US Launch of Ryzumvi Eye Drops to Reverse Pupil Dilation
Viatris and Ocuphire Pharma announced April 1 the US launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the reversal of pharmacologically induced mydriasis. The US FDA approved Ryzumvi ...
Aldeyra Outlines New Reproxalap Trial, Aims to Resubmit NDA in Dry Eye
Aldeyra Therapeutics on March 28 outlined its new clinical development plan for reproxalap eye drops, with the goal of resubmitting its new drug application (NDA) to the US FDA. The company said it...
Glaukos’ iDose Gets J-Code for Medical Billing in the US
The Centers for Medicare and Medicaid Services (CMS) has issued a J-code for Glaukos’ iDose. The billing code takes effect July 1, 2024. iDose TR gained US FDA approval under the 505(b)(2) pathway ...
Optical Chain to Exclusively Offer Verséa’s Biovance Ocular Allografts
West Point Optical Group, which operates 86 Pearle Vision clinics in 13 states, announced April 3 that it had reached an agreement with Verséa Ophthalmics to offer Verséa’s Biovance and Biovance 3L...
Beyeonics Vision Appoints A. Burton Tripathi, PhD, as CEO
Israel’s Beyeonics Vision announced March 28 that it had appointed A. Burton Tripathi, PhD, as its new chief executive officer. Tripathi was formerly CEO of TrueVision 3D Surgical. After Alcon acqu...
Nicox Appoints Gavin Spencer, PhD, as Chief Executive Officer
France’s Nicox announced that it had appointed Gavin Spencer, PhD, as chief executive officer, effective Feb. 28. Spencer was most recently executive vice president, chief business officer, and hea...
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay
Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...
Nanoscope Reports Positive Results for RP Optogenetic Therapy, Plans to file BLA in H2-2024
Nanoscope Therapeutics on March 26 reported positive topline results from its two-year Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monotherapy to restore vision in...
State Department Offers up to $10 Million for Info on Hackers of Change Healthcare
The US State Department announced March 27 that it was offering a reward of up to $10 million for information on ALPHV BlackCat-linked hackers targeting critical infrastructure in the US. The agenc...
Chambers Retires from US FDA After 36-Plus Years of Ophthalmic Drug Review
Wiley Chambers, MD, an ophthalmologist who conducted or supervised the review of ophthalmic drugs at the US FDA for 36 1/2 years, retired from the agency Jan. 13, 2024. The 65-year-old is now servi...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.